Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Deman... (h of DYNEPO in Italy and Ireland. Pro...)

Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track

Date:11/1/2007

h of DYNEPO in Italy and Ireland.

Product Divestment

On September 10, 2007 Shire sold EQUETRO(TM) (carbamazepine) to Validus Pharmaceuticals Inc. ("Validus") for a cash consideration of $7.5 million and transferred to Validus all post approval study commitments.

Recent Events

Class Action Shareholder suit

In January and February 2003, various parties filed purported securities fraud class action lawsuits against TKT and several of its former officers and directors in the United States District Court for the District of Massachusetts. In April 2003, the Court consolidated the various matters under one matter: In Re Transkaryotic Therapies, Inc., Securities Litigation, C.A. No 03-10165-RWZ. The plaintiffs alleged, among other things, that the defendants made false and misleading statements and failed to disclose material information regarding REPLAGAL during the period between January 4, 2001 and January 10, 2003. In October 2007, all the parties to the legal proceedings reached an agreement in principle to resolve the matter, subject to Court approval, for $50 million. Shire will contribute $27 million towards the settlement and its insurance carriers will contribute the remaining $23 million. The $27 million settlement cost has been provided for within SG&A during this quarter.

Further information on this litigation can be found in our filings with the US Securities and Exchange Commission ("SEC") including our Annual Report on Form 10-K for the year to December 31, 2006.

Product Divestments

On October 8, 2007 the Company announced the sale of a portfolio of non core products to Laboratorios Almirall S.A. ("Almirall") for a cash consideration of $213 million. The portfolio comprises the dermatology products SOLARAZE(R) (3% gel, diclofenac sodium (3%w/w)) and VANIQA(R) (eflornithine hydrochloride) and six non-promoted products across a range of indications, which are sold by Shire primarily in the UK, France, Germany, I
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine news :

1. Further support for use of statins in Alzheimer’s disease
2. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
3. Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered
4. NHS announces further Cost cutting Measures
5. NHS Recommends Further Cost Cutting Measures
6. Medha Patkars Condition Deteriorates Further
7. Oxford Radcliffe Hospitals Warns Of Further Job Losses
8. Asia Arming up to further the AIDS fight
9. Further Studies Needed To Completely Understand About Ventricular Fibrillation
10. Further improvements envisaged at Carstairs
11. UCLA Find Yields Further Insight into Causes of Parkinson’s Diseas

Post Your Comments:

(Date:5/21/2013)... 2013 Adeptia, a leading provider of ... announced it is the featured company in an impact ... The report, “Adeptia Bets on Converged Cloud Integration and ... its strategy, products, pricing, customers and competition. ... framework for integration and process orchestration, especially when price, ...

(Date:5/21/2013)... News) -- Chronic obstructive pulmonary disease (COPD) patients ... suggests. Pain levels are nearly on par ... osteoarthritis and rheumatoid arthritis patients, according to the ... the American Thoracic Society annual meeting in Philadelphia. ... pain medication use among COPD patients, and pain ...

(Date:5/21/2013)... 21 (HealthDay News) -- The risk of sudden infant ... sleep with their infant, a new study finds. ... SIDS even if parents do not drink, use illegal ... which is a major cause of infant death in ... sleep with their babies. In the United States, ...

(Date:5/21/2013)... News) -- The monstrous tornado that devastated Moore, ... children, is a stunning example of violent weather ... But even thunderstorms with lightning and strong winds ... Some anxiety in the face of ... storm phobias that interfere with their everyday lives, ...

(Date:5/21/2013)... charged gold nanoparticles are usually toxic to cells, ... toxicity. Mayo Clinic researchers found out why, and ... ovarian cancer cells. The discovery is detailed in ... of Biological Chemistry ., "This study identifies a ... preventing the cell death or apoptosis which should ...

Breaking Medicine News(10 mins):Health News:Adeptia Featured in Recent 451 Research Impact Report 2 Health News:Pain a Common Problem for People With COPD 2 Health News:Bed-Sharing Raises SIDS Risk Fivefold, Study Finds 2 Health News:Weather Worries Can Threaten a Child's Mental Health 2 Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2

[0] Adeptia Featured in Recent 451 Research Impact Report [0] Pain a Common Problem for People With COPD [0] Bed-Sharing Raises SIDS Risk Fivefold, Study Finds [0] Weather Worries Can Threaten a Child's Mental Health [0] Mayo Clinic: How gold nanoparticles can help fight ovarian cancer

... most previous work missed key DNA variant, researchers say ... structural changes in DNA called copy number variants may ... who said their findings support a sharp change of ... the past two decades, researchers have identified dozens of ...

... Corporate Governance,TUCSON, Ariz., Feb. 6 The Providence Service ... the recent announcement that an entity controlled by Avalon ... related persons, including Donald E. Smith, the CEO, controlling ... a consent solicitation against the Company. "We have no ...

... EVVV ) will release its 2008 fourth quarter ... on Tuesday, Febuary 24, 2009, before regular market trading hours.The ... day at 7:30 a.m. Central Time (8:30 a.m. Eastern Time). ... operating results and future outlook, followed by a question and ...

... year-to-date revenues increase by 35% over same period ... figures are in Canadian dollars unless otherwise noted),BELLEVILLE, ... Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical ... quarter of its 2009 fiscal year, ending December ...

... The rate of childhood obesity has risen significantly in ... younger ages. At the same time, the number of ... Now a new study finds that, contrary to conventional ... they,re playing outside. , The study, by an interdisciplinary ...

... view simulated results of breast enlargement in 3D, with accurate linear ... ... 5, 2009 -- Toronto Cosmetic Clinic introduces Axis Three,s Portrait 3D ... predicted results of breast augmentation almost instantaneously. ...

Genome Study Points to New Culprit for Schizophrenia Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc.ev3 Inc. to Report 2008 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 24, 2009 Bioniche Reports Fiscal 2009 Second Quarter Amid rising childhood obesity, preschoolers found to be inactive Toronto Cosmetic Clinic Offers Axis Three Breast Enlargement Imaging for the First Time in Canada

(Date:5/21/2013)... May 21, 2013 Reportlinker.com announces ... available in its catalogue: ... Scenario for Medical Devices in the US ... Changing Regulatory and Reimbursement ... Market Summary ...

(Date:5/21/2013)... Calif. , May 21, 2013 /PRNewswire/ ... ), a specialty pharmaceutical company focused on ... for the treatment of acute and breakthrough ... in a placebo-controlled Phase 3 study of ... analgesia) System (NanoTab System), the primary efficacy ...

(Date:5/21/2013)... and HENDERSONVILLE, N.C. , May ... procurement program for home medical equipment is forcing ... Carolina to lay off employees or close ... of service and products received by Medicare beneficiaries, says ... defective and dangerous program, the Centers for Medicare ...

[0] Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market [0] Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain [0] North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program

... CareFusion today announced an agreement to acquire PHACTS, ... hospital pharmacies better manage inventory, reduce pharmaceutical costs and ... The acquisition will advance CareFusion,s strategy to ... medication throughout their facilities – from the loading ...

... /PRNewswire-Asia/ -- At this very moment, FIRMOO is being heatedly ... of eyeglasses from FIRMOO are being delivered to various countries ... by so many eyeglasses wearers? In this brand new year ... sales platforms, is giving away thousands of free eyeglasses every ...

Cached Medicine Technology:CareFusion To Acquire Pharmacy Automation Technology Leader 2 CareFusion To Acquire Pharmacy Automation Technology Leader 3 CareFusion To Acquire Pharmacy Automation Technology Leader 4 Free Glasses from FIRMOO - Welcome to Your Glasses Kingdom 2 Free Glasses from FIRMOO - Welcome to Your Glasses Kingdom 3

CareFusion To Acquire Pharmacy Automation Technology Leader Free Glasses from FIRMOO - Welcome to Your Glasses Kingdom

Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....

For use with catalog #0454....

Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....

Medicine Products:

Drugs of Abuse Array Cocaine Metabolite Assay D-DI TEST CARDS D-DI LATEX STA LIATEST D-DI